Deloitte.

Reff Associates

Tax & Legal Weekly Alert

3 – 7 November 2014

Articles in this issue

Tax Updates

Latest amendments regarding the claw-back tax in Romania

The Government amended the Emergency Ordinance 77/2011 regarding the claw-back tax. Based on the new provisions, the market authorizations holders/their legal representatives will pay a different clawback tax for the medicines conditionally included in the list of compensated medicines for which costvolume/cost-volume-result agreements were concluded - page 2



Latest amendments regarding the claw-back tax in Romania

The main amendments are:

- It is now clearly mentioned that the consumption of medicines communicated by the pharmacies to the National Health Insurance House includes VAT and that the claw-back tax due shall be computed after the VAT is deducted from the values of consumption communicated by the National Health Insurance House.
- A new mechanism for computing the claw-back tax is introduced. This applies only for the medicines admitted conditionally on the list of compensated medicines for which a cost-volume/cost-volume-result agreement is concluded between the market authorization holder, the National Health Insurance House and the Ministry of Health.
- The claw-back tax due for these medicines will be computed by applying a percentage "p" (mentioned in the costvolume/cost-volume-result agreement) to the quarterly value of medicine consumption.
- The value of consumption will be established by taking into account the sale price, without VAT, and the volume of consumption of medicines, as established in the costvolume/cost-volume-result agreement.
- If the consumption volume mentioned in the cost-volume/cost-volume- result is exceeded, the market authorization holder will pay the full amount of the exceeding consumption of medicines, excluded of VAT.
- The percentage "p" will be computed taking into consideration its value from the quarter prior to signing the cost-volume agreements plus 5 to 30 percentage points, depending on the number of contractible patients for each therapy compared to the number of eligible patients.

The above provisions come into effect starting November 5th, 2014.

Please do not hesitate to contact us if any clarification is needed:

Dan Badin

Tax and Legal Partner-in-Charge +40 21 207 53 92

Daniel Petre

Director +40 21 207 54 44

Vlad Boeriu

Director

+40 21 207 53 41



Romania@deloittece.com or visit the web page www.deloitte.com/ro/tax-alerts	
This Alert is provided as a guide only and should not be construed as advice. Professional tax/legal advice should be sought before acting upon any of this document.	ne points raised in
This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, any of its member firms or any of the foregoing's affiling Deloitte Network") are, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services, nor should it be used as a basis for any decision or action that may affect your finances. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional advice Network shall be responsible for any loss whatsoever sustained by any person who relies on this publication.	vices. This ances or your
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each	

Deloitte provides audit, tax, consulting, and financial advisory services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex

business challenges. Deloitte has in the region of 200,000 professionals, all committed to becoming the standard of excellence.

firms.